Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 03 2020
revised: 29 04 2020
accepted: 12 05 2020
pubmed: 2 6 2020
medline: 1 9 2021
entrez: 2 6 2020
Statut: ppublish

Résumé

Ex vivo lung perfusion (EVLP) allows for a reassessment of lung grafts initially deemed unsuitable for transplantation, increasing the available donor pool; however, this requires a pre- and post-EVLP period of cold ischemic time (CIT). Paucity of data exists on how the sequence of cold normothermic-cold preservations affect outcomes. A total of 110 patients were retrospectively analyzed. Duration of 3 preservation phases was measured: cold pre-EVLP, EVLP, and cold post-EVLP. The donor and recipient clinical data were collected. Primary graft dysfunction (PGD) and survival were monitored. Risk of mortality or PGD was calculated using Cox proportional hazards and logistic regression models to adjust for baseline characteristics. Using the highest quartile, patients were stratified into extended vs non-extended pre-EVLP (<264 vs ≥264 minutes) and post-EVLP (<287 vs ≥287 minutes) CIT. The rates of 1-year mortality (8.4% vs 29.6%, p = 0.013), PGD 2-3 (20.5% vs 52%, p = 0.002), and PGD 3 (8.4% vs 29.6%, p = 0.005) at 72 hours were increased in the extended post-EVLP CIT group. After adjusting for baseline risk factors, the extended group remained an independent predictor of PGD ≥2 (odd ratio: 6.18, 95% CI: 1.88-20.3, p = 0.003) and PGD 3 (odd ratio: 20.4, 95% CI: 2.56-161.9, p = 0.004) at 72 hours and 1-year mortality (hazard ratio: 17.9, 95% CI: 3.36-95.3, p = 0.001). Cold pre-EVLP was not a significant predictor of primary outcomes. Extended cold post-EVLP preservation is associated with a risk for PGD and 1-year mortality. Pre-EVLP CIT does not increase mortality or high-grade PGD. These findings from a multicenter trial should caution on the implementation of extended cold preservation after EVLP.

Sections du résumé

BACKGROUND
Ex vivo lung perfusion (EVLP) allows for a reassessment of lung grafts initially deemed unsuitable for transplantation, increasing the available donor pool; however, this requires a pre- and post-EVLP period of cold ischemic time (CIT). Paucity of data exists on how the sequence of cold normothermic-cold preservations affect outcomes.
METHODS
A total of 110 patients were retrospectively analyzed. Duration of 3 preservation phases was measured: cold pre-EVLP, EVLP, and cold post-EVLP. The donor and recipient clinical data were collected. Primary graft dysfunction (PGD) and survival were monitored. Risk of mortality or PGD was calculated using Cox proportional hazards and logistic regression models to adjust for baseline characteristics.
RESULTS
Using the highest quartile, patients were stratified into extended vs non-extended pre-EVLP (<264 vs ≥264 minutes) and post-EVLP (<287 vs ≥287 minutes) CIT. The rates of 1-year mortality (8.4% vs 29.6%, p = 0.013), PGD 2-3 (20.5% vs 52%, p = 0.002), and PGD 3 (8.4% vs 29.6%, p = 0.005) at 72 hours were increased in the extended post-EVLP CIT group. After adjusting for baseline risk factors, the extended group remained an independent predictor of PGD ≥2 (odd ratio: 6.18, 95% CI: 1.88-20.3, p = 0.003) and PGD 3 (odd ratio: 20.4, 95% CI: 2.56-161.9, p = 0.004) at 72 hours and 1-year mortality (hazard ratio: 17.9, 95% CI: 3.36-95.3, p = 0.001). Cold pre-EVLP was not a significant predictor of primary outcomes.
CONCLUSIONS
Extended cold post-EVLP preservation is associated with a risk for PGD and 1-year mortality. Pre-EVLP CIT does not increase mortality or high-grade PGD. These findings from a multicenter trial should caution on the implementation of extended cold preservation after EVLP.

Identifiants

pubmed: 32475748
pii: S1053-2498(20)31554-0
doi: 10.1016/j.healun.2020.05.002
pii:
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

954-961

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL143000
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Auteurs

Miguel M Leiva-Juárez (MM)

Section of General Thoracic Surgery, Lung Transplant Program, Columbia University Medical Center, New York, New York.

Andreacarola Urso (A)

Section of General Thoracic Surgery, Lung Transplant Program, Columbia University Medical Center, New York, New York.

Elisabet Arango Tomás (E)

Section of General Thoracic Surgery, Lung Transplant Program, Columbia University Medical Center, New York, New York.

David J Lederer (DJ)

Section of General Thoracic Surgery, Lung Transplant Program, Columbia University Medical Center, New York, New York.

Pablo Sanchez (P)

Department of Cardiac Surgery, University of Maryland Medical Center, Baltimore, Maryland.

Bartley Griffith (B)

Department of Cardiac Surgery, University of Maryland Medical Center, Baltimore, Maryland.

R Duane Davis (RD)

Department of Cardiovascular and Thoracic Surgery, Duke University, Durham, North Carolina.

Mani Daneshmand (M)

Department of Cardiovascular and Thoracic Surgery, Duke University, Durham, North Carolina.

Matthew Hartwig (M)

Department of Cardiovascular and Thoracic Surgery, Duke University, Durham, North Carolina.

Edward Cantu (E)

Division of Cardiac Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.

Michael J Weyant (MJ)

Department of Cardiothoracic Surgery, University of Colorado Denver, Denver, Colorado.

Christian Bermudez (C)

Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jonathan D'Cunha (J)

Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Tiago Machuca (T)

Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, Florida.

Thomas Wozniak (T)

Department of Cardiothoracic Surgery, Indiana University, Bloomington, Indiana.

William Lynch (W)

Department of Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.

Hassan Nemeh (H)

Department of Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.

Michael Mulligan (M)

Department of Thoracic Surgery, University of Washington, Seattle, Washington.

Tae Song (T)

Division of Cardiothoracic Surgery, University of Chicago, Chicago, Illinois.

Michael Jessen (M)

Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, Texas.

Phillip C Camp (PC)

Department of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.

Christiano Caldeira (C)

Department of Thoracic Surgery, Largo Medical Center, Largo, Florida.

Bryan Whitson (B)

Division of Cardiac Surgery, Ohio State University, Columbus, Ohio.

Daniel Kreisel (D)

Department of Cardiothoracic Surgery, Barnes Jewish Hospital, Saint Louis, Missouri.

Danny Ramzy (D)

Department of Cardiothoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, California.

Frank D'Ovidio (F)

Section of General Thoracic Surgery, Lung Transplant Program, Columbia University Medical Center, New York, New York. Electronic address: fd2133@cumc.columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH